Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179673 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase 2 study of Non-Hodgkin's Lymphoma, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 15
- Study locations
NCT00179673 is a Phase 2 study of Non-Hodgkin's Lymphoma that has completed, run by Celgene. The registered enrollment target is 43 participants, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (81% lower). The trial reports 15 study locations across 13 states.
The verdict
NCT00179673, a Phase 2 study of Non-Hodgkin's Lymphoma, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 15
- Study locations
Study Summary
Subjects who qualify will receive lenalidomide daily on days 1-21 of every 28-day cycle. Treatment will continue for up to 52 weeks or until disease progression; subjects who achieve a Complete Response (CR) will receive an additional 2 cycles of treatment prior to discontinuation. Subjects will be followed for progression free survival following discontinuation from the treatment phase
Conditions Studied
Interventions
- DRUG Lenalidomide
Study Locations (15)
California
- Alta Bates Cancer Center - Berkeley
- Pacific Coast Hematology/Oncology Medical Group, Onc. - Fountain Valley
British Columbia
- BC Community Oncology Trialist - Burnaby
- BC Community Oncology - North Vancouver
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Illinois
- Rush University Medical Center - Chicago
Massachusetts
- Harvard University - Boston
Minnesota
- Mayo Clinic - Rochester
Nebraska
- University of Nebraska - Omaha
New York
- New York Medical Center, MBCCOP - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179673
The ClinicalTrials.gov registry entry for NCT00179673 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (81% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Lenalidomide is the first listed.
NCT00179673 reports 15 study locations spanning 13 distinct geographic areas - top geographies include California, British Columbia, Arizona.
Frequently Asked Questions
What is clinical trial NCT00179673 about?
NCT00179673 is a clinical study titled "Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma". Subjects who qualify will receive lenalidomide daily on days 1-21 of every 28-day cycle. Treatment will continue for up to 52 weeks or until disease progression; subjects who achieve a Complete Response (CR) will receive an additional 2 cycles of treatment prior to discontinuation. Subjects will be ...
What is the current status of trial NCT00179673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2005-06. Estimated completion is 2008-04.
What conditions does trial NCT00179673 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00179673?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00179673?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00179673 being conducted?
This trial has 15 study locations across Arizona, California, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
RECRUITING · Phase 2
-
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.